A Phase II, Single Arm, Open Label Study of Treatment-Free Remission in Chronic Myeloid Leukemia (CML) chronic phase (CP) patients After Achieving Sustained MR4.5 on Nilotinib
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ENESTop
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 30 Jul 2024 Planned End Date changed from 20 Jan 2025 to 19 Jan 2025.
- 05 Jul 2024 Planned End Date changed from 24 Jan 2025 to 20 Jan 2025.
- 29 May 2024 Planned End Date changed from 31 Jan 2025 to 24 Jan 2025.